FLOW trial stopped early due to evidence of renal protection with semaglutide

Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.

Authors

Felice Gragnano^{1

2}, Vincenzo De Sio^{1

2}, Paolo Calabrò^{1

2}

Affiliations

¹ Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Abramo Lincoln 5 - 81100 Caserta, Italy.
² Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Ferdinando Palasciano - 81100 Caserta, Italy.

PMID: 37934595
DOI: 10.1093/ehjcvp/pvad080

No abstract available

MeSH terms

Clinical Trials as Topic
Glucagon-Like Peptides* / therapeutic use
Humans
Kidney*

Substances

Glucagon-Like Peptides
semaglutide